From the Globe and Mail:
Just one year after it was approved for use in Canada, federal health officials are investigating safety concerns about smoking cessation prescription drug Champix amid fears it is linked to suicide and serious psychological problems.
The investigation and reports of major side effects highlight what many medical experts describe as chronic problems with the way new drugs are approved in Canada and the ability of government officials to adequately monitor them once they're put on the market.
"Existing systems don't really seem to be adequate," said David Henry, chief executive officer of the Institute for Clinical Evaluative Sciences in Toronto. "That means often times the studies that are the basis for market approval are not large enough to test for safety properly." ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment